Lilly, Zepbound and weight loss
Digest more
Discover why Eli Lilly's stock downturn may present new opportunities. Learn about valuation, Zepbound pricing, and 2026 ...
Eli Lilly's decision to reduce the price of its popular weight loss drug makes more sense than it appears at first. The ...
Eli Lilly & Co. is cutting the price for introductory doses of its weight-loss drug Zepbound again, as competition heats up ...
In an added benefit, more than one in eight people taking the highest dose of Retratrutide were completely free of arthritic ...
Eli Lilly’s weight loss drugs have delivered blockbuster sales in recent quarters. The company is a leader in this market ...
Eli Lilly said it has lowered the price of single-dose vials of its popular obesity drug Zepbound to make the treatment more ...
LLY leans on tirzepatide and a deep late-stage pipeline to defend its obesity momentum as new rivals make rapid progress in ...
Abbott Laboratories (NYSE: ABT) and Eli Lilly (NYSE: LLY) just reported Q3 earnings that highlight two fundamentally ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback